AKT1 and cancer: It has been suggested that PARPi activate AKT to induce resistance in cancer therapies (8), however, constitutive activation of AKT or AKT hyperactivation inhibits FOXO, leading to myeloid maturation and subsequent cell death in acute myeloid leukemia (AML) cells (29).